CagriSema: difference between revisions
Diff·revision 1 → 2·03:36, 23 Oct 2024
Difference between revision 1 and revision 2 of CagriSema. 5 lines changed; the page grew by 562 bytes.
| Revision 1 — 23:41, 18 Oct 2024 MergeMorwenna (talk) create article — compound stub 1,661 bytes +1,661 | Revision 2 — 03:36, 23 Oct 2024 LiraLotte (talk) expand §Reported findings 2,223 bytes +562 | ||
|---|---|---|---|
| 11 | It differs architecturally from the [[Dual incretin agonist|unimolecular dual agonists]]: rather than one peptide engaging two receptors, CagriSema is two peptides in one syringe. The ratio is therefore set at formulation rather than by chemistry, and the two components retain their own pharmacokinetics — an advantage for design flexibility and a complication for exposure matching.{{r|lau2021}} | 11 | It differs architecturally from the [[Dual incretin agonist|unimolecular dual agonists]]: rather than one peptide engaging two receptors, CagriSema is two peptides in one syringe. The ratio is therefore set at formulation rather than by chemistry, and the two components retain their own pharmacokinetics — an advantage for design flexibility and a complication for exposure matching.{{r|lau2021}} |
| 12 | 12 | ||
| + | 13 | == Rationale == | |
| + | 14 | Amylin acts principally at the area postrema through calcitonin-receptor complexes; GLP-1 acts at the area postrema and at hypothalamic [[Arcuate nucleus|arcuate]] circuits through the [[GLP-1 receptor]]. The pathways converge on food intake but are pharmacologically separable, and preclinical work indicated additivity rather than redundancy.{{r|lau2021}} | |
| + | 15 | ||
| + | 16 | Both components also slow [[Gastric emptying|gastric emptying]], which is where the mechanisms overlap most and where the tolerability cost of combining them is expected to concentrate. | |
| + | 17 | ||
| 13 | == References == | 18 | == References == |
| 14 | {{reflist}} | 19 | {{reflist}} |